Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Wynne

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 16, 2005
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitorsKwai-Ming J Cheung, Thomas P Matthews, Karen James, et al.
Journal of Medicinal Chemistry|March 13, 2012
Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activityPaolo Innocenti, Kwai-Ming J Cheung, Savade Solanki, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Molecular Cancer Therapeutics|January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106Michael I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry|July 4, 2009
Identification of inhibitors of checkpoint kinase 1 through template screeningThomas P Matthews, Suki Klair, Samantha Burns, et al.
Plos One|January 19, 2012
Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signallingSimon R Stockwell, Georgina Platt, S Elaine Barrie, et al.
Journal of Medicinal Chemistry|October 13, 2010
Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterizationDaniel K Whelligan, Savade Solanki, Dawn Taylor, et al.
Journal of Medicinal Chemistry|December 29, 2010
Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2John J Caldwell, Emma J Welsh, Cornelis Matijssen, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|September 22, 2016
Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registryTimothy R Betts, Milena Leo, Sandeep Panikker, et al.
Plos One|June 19, 2013
Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2M Cris Silva-Santisteban, Isaac M Westwood, Kathy Boxall, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Bioorganic & Medicinal Chemistry Letters|June 16, 2005
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitorsKwai-Ming J Cheung, Thomas P Matthews, Karen James, et al.
Journal of Medicinal Chemistry|March 13, 2012
Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activityPaolo Innocenti, Kwai-Ming J Cheung, Savade Solanki, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinasesThomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Molecular Cancer Therapeutics|January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106Michael I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry|July 4, 2009
Identification of inhibitors of checkpoint kinase 1 through template screeningThomas P Matthews, Suki Klair, Samantha Burns, et al.
Plos One|January 19, 2012
Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signallingSimon R Stockwell, Georgina Platt, S Elaine Barrie, et al.
Journal of Medicinal Chemistry|October 13, 2010
Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterizationDaniel K Whelligan, Savade Solanki, Dawn Taylor, et al.
Journal of Medicinal Chemistry|December 29, 2010
Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2John J Caldwell, Emma J Welsh, Cornelis Matijssen, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|September 22, 2016
Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: A multicenter registryTimothy R Betts, Milena Leo, Sandeep Panikker, et al.
Plos One|June 19, 2013
Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2M Cris Silva-Santisteban, Isaac M Westwood, Kathy Boxall, et al.
Pageof 10